title: Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.
abstract: OBJECTIVE
  The effect of pitavastatin on high-sensitivity C-reactive protein (hs-CRP) has not been reported, yet, in humans. We, therefore, investigated the effects of pitavastatin on lipid profiles and hs-CRP in Japanese subjects with hypercholesterolemia.
  
  
  METHODS
  The subjects were 178 Japanese with hypercholesterolemia, including 103 (58%) with type 2 diabetes. Pitavastatin (12 mg/day) was administered for 12 months. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), triglycerides (TG) and hs-CRP levels were measured for 12 months.
  
  
  RESULTS
  Serum LDL-C and RLP-C levels were significantly decreased by 30.3% and 22.8%, respectively. Serum TG levels were decreased by 15.9% in subjects with basal TG levels above 150 mg/dl. Serum HDL-C levels were significantly increased. The administration of pitavastatin reduced serum hs-CRP levels by 34.8%. No serious adverse events were observed, including changes in glycosylated hemoglobin levels of diabetic patients.
  
  
  CONCLUSIONS
  These results suggest that pitavastatin significantly improves lipid profiles and reduces proinflammatory responses, without adverse effects, in Japanese subjects with hypercholesterolemia, including those with diabetes mellitus.
authors.affiliation: Center for Diabetes & Endocrinology, The Tazuke Kofukai Foundation Medical Research Institute Kitano Hospital, Osaka, Japan. h-koshiyama@kitano-hp.or.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Koshiyama
authors.forename: Ataru
authors.initials: A
authors.lastname: Taniguchi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shinji
authors.initials: S
authors.lastname: Kagimoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Fujioka
authors.forename: Kenichi
authors.initials: K
authors.lastname: Hirata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Akane
authors.initials: A
authors.lastname: Iwakura
authors.forename: Kyoko
authors.initials: K
authors.lastname: Hara
authors.forename: Taizo
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Akira
authors.initials: A
authors.lastname: Kuroe
authors.forename: Michihiro
authors.initials: M
authors.lastname: Ohya
authors.forename: Shimpei
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Sachiko
authors.initials: S
authors.lastname: Honjo
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Koichiro
authors.initials: K
authors.lastname: Nabe
authors.forename: Kinsuke
authors.initials: K
authors.lastname: Tsuda
authors.forename: Nobuya
authors.initials: N
authors.lastname: Inagaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Seino
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kume
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007564:Japan; D008055:Lipids / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D014280:Triglycerides; D002097:C-Reactive Protein; C108475:pitavastatin